Wellington Shields & Co. LLC Trims Stake in CVS Health Co. (NYSE:CVS)

Wellington Shields & Co. LLC reduced its position in shares of CVS Health Co. (NYSE:CVSFree Report) by 20.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 22,747 shares of the pharmacy operator’s stock after selling 5,959 shares during the quarter. Wellington Shields & Co. LLC’s holdings in CVS Health were worth $1,021,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of CVS. Versor Investments LP purchased a new position in shares of CVS Health in the 3rd quarter valued at $371,000. GSA Capital Partners LLP purchased a new position in shares of CVS Health in the 3rd quarter valued at $816,000. Aptus Capital Advisors LLC increased its holdings in shares of CVS Health by 7.7% in the 3rd quarter. Aptus Capital Advisors LLC now owns 12,078 shares of the pharmacy operator’s stock valued at $759,000 after acquiring an additional 865 shares during the period. MQS Management LLC purchased a new position in shares of CVS Health in the 3rd quarter valued at $237,000. Finally, Oppenheimer & Co. Inc. increased its holdings in shares of CVS Health by 5.6% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 99,848 shares of the pharmacy operator’s stock valued at $6,278,000 after acquiring an additional 5,325 shares during the period. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Stock Performance

Shares of CVS stock opened at $65.63 on Friday. The stock has a market cap of $82.75 billion, a PE ratio of 17.93, a price-to-earnings-growth ratio of 0.98 and a beta of 0.53. The business has a 50-day simple moving average of $58.47 and a 200-day simple moving average of $57.00. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $80.75.

CVS Health (NYSE:CVSGet Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, equities analysts expect that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were paid a $0.665 dividend. The ex-dividend date was Thursday, January 23rd. This represents a $2.66 annualized dividend and a dividend yield of 4.05%. CVS Health’s dividend payout ratio is presently 72.68%.

Insider Activity at CVS Health

In other CVS Health news, Director Michael F. Mahoney purchased 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was purchased at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the purchase, the director now directly owns 39,356 shares in the company, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the transaction, the senior vice president now owns 8,394 shares of the company’s stock, valued at approximately $556,941.90. This represents a 47.23 % decrease in their position. The disclosure for this sale can be found here. 0.24% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on CVS shares. Piper Sandler cut their price target on CVS Health from $72.00 to $64.00 and set an “overweight” rating on the stock in a report on Monday, November 25th. JPMorgan Chase & Co. raised their price objective on CVS Health from $80.00 to $81.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 18th. StockNews.com raised CVS Health from a “sell” rating to a “hold” rating in a research report on Thursday, February 13th. Cantor Fitzgerald raised CVS Health from a “neutral” rating to an “overweight” rating in a research report on Wednesday, February 12th. Finally, Evercore ISI raised their price objective on CVS Health from $60.00 to $65.00 and gave the stock an “outperform” rating in a research report on Monday, January 27th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $69.83.

Check Out Our Latest Report on CVS

CVS Health Company Profile

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Recommended Stories

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVSFree Report).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.